Immunic Reports P-II (EMPhASIS) Trial Results of IMU-838 (vidofludimus calcium) for the Treatment of Relapsing-Remitting Multiple Sclerosis
Shots:
- The P-II (EMPhASIS) trial evaluating the efficacy & safety of vidofludimus calcium (10/30/45mg) vs PBO in patients aged 18-55yrs. with RRMS
- The results showed encouraging signals in preventing 12 & 24wk. confirmed disability worsening events (12w/24wCDW) in 1.6% vs 3.7% of patients, patients were free from 12wCDW in the OLE phase was 97.6% after 48wks. and 94.5% after 96wks. of vidofludimus calcium treatment over the start of the OLE phase, similar results were observed for 24wCDW and sustained CDW with low relapse activity
- Vidofludimus calcium is an orally available, next-generation selective immune modulator that inhibited the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase (DHODH)
Ref: PR Newswire | Image: Immunic
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
